PET in Cardiac Sarcoidosis.

Authors

Chetan D Patel, Aman Tilak, Chakshine Shiva

Published in

PET clinics. Oct 07, 2026. Epub Oct 07, 2026.

Abstract

¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) PET is used to diagnose cardiac sarcoidosis (CS) in patients with extracardiac sarcoidosis and suspected cardiac involvement or suspected isolated CS. Rigorous patient preparation suppresses physiological myocardial uptake. ¹⁸F-FDG PET is interpreted with myocardial perfusion imaging: abnormal uptake with normal perfusion indicates inflammation without fibrosis, uptake with a perfusion defect indicates inflammation with fibrosis, and a perfusion defect without uptake indicates fibrosis alone. Abnormal uptake, particularly with perfusion defects, predicts major adverse cardiac events, including death and ventricular arrhythmias. Serial ¹⁸F-FDG PET monitors response to immunosuppressive therapy and detects reactivation of myocardial inflammation.

PMID:
42844072
Bibliographic data and abstract were imported from PubMed on 08 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.